Which terms should be used to describe medications used in the treatment of seizure disorders? An ILAE position paper.
antiepileptic drugs
antiseizure medications
recommendations
terminology
Journal
Epilepsia
ISSN: 1528-1167
Titre abrégé: Epilepsia
Pays: United States
ID NLM: 2983306R
Informations de publication
Date de publication:
Mar 2024
Mar 2024
Historique:
revised:
16
12
2023
received:
22
08
2022
accepted:
02
01
2024
pubmed:
27
1
2024
medline:
27
1
2024
entrez:
27
1
2024
Statut:
ppublish
Résumé
A variety of terms, such as "antiepileptic," "anticonvulsant," and "antiseizure" have been historically applied to medications for the treatment of seizure disorders. Terminology is important because using terms that do not accurately reflect the action of specific treatments may result in a misunderstanding of their effects and inappropriate use. The present International League Against Epilepsy (ILAE) position paper used a Delphi approach to develop recommendations on English-language terminology applicable to pharmacological agents currently approved for treating seizure disorders. There was consensus that these medications should be collectively named "antiseizure medications". This term accurately reflects their primarily symptomatic effect against seizures and reduces the possibility of health care practitioners, patients, or caregivers having undue expectations or an incorrect understanding of the real action of these medications. The term "antiseizure" to describe these agents does not exclude the possibility of beneficial effects on the course of the disease and comorbidities that result from the downstream effects of seizures, whenever these beneficial effects can be explained solely by the suppression of seizure activity. It is acknowledged that other treatments, mostly under development, can exert direct favorable actions on the underlying disease or its progression, by having "antiepileptogenic" or "disease-modifying" effects. A more-refined terminology to describe precisely these actions needs to be developed.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
533-541Subventions
Organisme : NINDS NIH HHS
ID : U01 NS088034
Pays : United States
Organisme : NINDS NIH HHS
ID : U54 NS100064
Pays : United States
Informations de copyright
© 2024 The Authors. Epilepsia published by Wiley Periodicals LLC on behalf of International League Against Epilepsy.
Références
Brodie MJ. Antiepileptic drug therapy the story so far. Seizure. 2010;19(10):650-655.
Perucca E. Antiepileptic drugs: evolution of our knowledge and changes in drug trials. Epileptic Disord. 2019;21(4):319-329.
Somerville E. Comments on Dhevender Bhalla et al. “Anti-epileptic drugs: is terminology appropriate: a change might be needed”. Neurol Asia. 2015;20(2):119.
Bhalla D, Ross S, Loftalinezhad E, Kapoor S, Heng LK, Raingsey PP, et al. Anti-epileptic drugs: is terminology appropriate? A change might be needed. Neurol Asia. 2015;20(2):117.
French JA, Perucca E. Time to start calling things by their own names? The case for antiseizure medicines. Epilepsy Curr. 2020;20(2):69-72.
Temkin NR. Antiepileptogenesis and seizure prevention trials with antiepileptic drugs: metaanalysis of controlled trials. Epilepsia. 2001;42:515-524.
Löscher W, Klein P. The pharmacology and clinical efficacy of antiseizure medications: from bromide salts to cenobamate and beyond. CNS Drugs. 2021;35(9):935-963.
Institute of Medicine (US) Committee on the Public Health Dimensions of the Epilepsies. In: England MJ, Liverman CT, Schultz AM, Strawbridge LM, editors. Epilepsy across the Spectrum. Promoting health and understanding. Washington DC: National Academies Press; 2012.
Trinka E, Brigo F. Antiepileptogenesis in humans: disappointing clinical evidence and ways to move forward. Curr Opin Neurol. 2014;27(2):227-235.
Galanopoulou AS, Löscher W, Lubbers L, O'Brien TJ, Staley K, Vezzani A, et al. Antiepileptogenesis and disease modification: Progress, challenges, and the path forward. Report of the preclinical working group of the 2018 NINDS-sponsored antiepileptogenesis and disease modification workshop. Epilepsia Open. 2021;6(2):276-296.
Löscher W, Klein P. New approaches for developing multi-targeted drug combinations for disease modification of complex brain disorders. Does epilepsy prevention become a realistic goal? Pharmacol Ther. 2022;229:107934.
Dalkey N, Helmer O. An experimental application of the DELPHI method to the use of experts. Manag Sci. 1963;9:458-467.
Popkirov S, Asadi-Pooya AA, Duncan R, Gigineishvili D, Hingray C, Kanner AM, et al. The aetiology of psychogenic non-epileptic seizures: risk factors and comorbidities. Epileptic Disord. 2019;21(6):529-547.
Fisher RS, van Emde BW, Blume W, Elger C, Genton P, Lee P, et al. Epileptic seizures and epilepsy: definitions proposed by the international league against epilepsy (ILAE) and the International Bureau for Epilepsy (IBE). Epilepsia. 2005;46(4):470-472.
Lopez MR, LaFrance WC. Treatment of psychogenic nonepileptic seizures. Curr Neurol Neurosci Rep. 2022;22(8):467-474.
Gaskell C, Power N, Novakova B, Simmonds-Buckley M, Reuber M, Kellett S, et al. A meta-analytic review of the effectiveness of psychological treatment of functional/dissociative seizures on non-seizure outcomes in adults. Epilepsia. 2023;64(7):1722-1738.
Kim HD, Kang HC, Lee SA, Huh K, Lee BI. Changing name of epilepsy in Korea; cerebroelectric disorder (noi-jeon-jeung, 뇌전증,): my epilepsy story. Epilepsia. 2014;55(3):384-386.
Brodie MJ, Covanis A, Gil-Nagel A, Lerche H, Perucca E, Sills GJ, et al. Antiepileptic drug therapy: does mechanism of action matter? Epilepsy Behav. 2011;21(4):331-341.
Margolis JM, Chu BC, Wang ZJ, Copher R, Cavazos JE. Effectiveness of antiepileptic drug combination therapy for partial-onset seizures based on mechanisms of action. JAMA Neurol. 2014;71(8):985-993.
Scheffer IE, Liao J. Deciphering the concepts behind "epileptic encephalopathy" and "developmental and epileptic encephalopathy". Eur J Paediatr Neurol. 2020;24:11-14.
Gillinder L, Britton J. Autoimmune-associated seizures. Continuum (Minneap Minn). 2022;28(2):363-398.